Bloom Burton reissued their hold rating on shares of Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) in a research report sent to investors on Monday morning.

A number of other research firms also recently weighed in on MSL. Scotiabank restated a sector perform rating and issued a C$1.25 target price on shares of Merus Labs International in a report on Monday. Paradigm Capital reduced their target price on shares of Merus Labs International from C$1.60 to C$1.00 and set a hold rating on the stock in a report on Thursday, December 15th. TD Securities reduced their target price on shares of Merus Labs International from C$4.00 to C$3.00 and set a buy rating on the stock in a report on Thursday, December 15th. Canaccord Genuity reduced their target price on shares of Merus Labs International from C$3.50 to C$3.00 and set a buy rating on the stock in a report on Thursday, December 15th. Finally, Royal Bank Of Canada reduced their target price on shares of Merus Labs International from C$3.50 to C$3.00 in a report on Thursday, December 15th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average price target of C$2.11.

Merus Labs International (TSE:MSL) opened at 1.13 on Monday. Merus Labs International has a 52 week low of $0.95 and a 52 week high of $2.20. The firm’s 50 day moving average is $1.09 and its 200-day moving average is $1.24. The company’s market cap is $132.21 million.

This piece of content was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this piece of content can be read at http://www.dailypolitical.com/2017/02/16/merus-labs-international-inc-msl-earns-hold-rating-from-bloom-burton.html.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.